Sugi Predict

Sugi Predict / Compounds / P-Tolyl Dimethylcarbamate

P-Tolyl Dimethylcarbamate

P-Tolyl Dimethylcarbamate

SCHEMBL360147

Cc1ccc(OC(=O)N(C)C)cc1

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.83
▸ KMT2A Q03164 3/20 0.59
▸ ALDH1A1 P00352 3/20 0.59
▸ NPSR1 Q6W5P4 2/20 0.59
▸ PKM P14618 2/20 0.59
▸ GAA P10253 1/20 0.59
▸ LMNA P02545 5/20 0.59
▸ NCEH1 Q6PIU2 1/20 0.53
▸ MAPT P10636 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ TSHR P16473 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ BCHE P06276 5/20 0.49
▸ ACHE P22303 5/20 0.49
▸ GLA P06280 2/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ NFKB2 Q00653 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450091 0.91 RAB9A (1.00) RAB9AKMT2AALDH1A1NPSR1PKM
SCHEMBL18602051 0.83 RAB9A (0.57) RAB9AKMT2AALDH1A1NPSR1PKM
SCHEMBL29313266 0.83 RAB9A (0.57) RAB9AKMT2AALDH1A1NPSR1PKM
SCHEMBL9203037 0.81 RAB9A (0.79) RAB9AKMT2AALDH1A1NPSR1PKM
SCHEMBL11783210 0.81 LMNA (0.57) RAB9AKMT2AALDH1A1NPSR1PKM
SCHEMBL360146 0.81 RAB9A (0.79) RAB9AKMT2AALDH1A1NPSR1PKM
SCHEMBL15139541 0.81 RAB9A (0.79) RAB9AKMT2AALDH1A1NPSR1PKM
SCHEMBL9301148 0.81 RAB9A (0.79) RAB9AKMT2AALDH1A1NPSR1PKM
4-Chlorophenyl Dimethylcarbamate SCHEMBL11300470 0.81 RAB9A (0.79) RAB9AKMT2AALDH1A1NPSR1PKM
SCHEMBL12994626 0.80 RAB9A (0.53) RAB9AKMT2AALDH1A1NPSR1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593425-B1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE AGIOS PHARMACEUTICALS INC (US) 2018-10-17 — — EP claimed
US-20160264621-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2016-09-15 — — US claimed
US-20130184222-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2013-07-18 — — US claimed
EP-2593425-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE Agios Pharmaceuticals, Inc. (US) 2013-05-22 — — EP claimed
WO-2012009678-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE AGIOS PHARMACEUTICALS, INC. (US) 2012-01-19 — — WO claimed
WO-2022203930-A9 FLUOROGENIC CYANINE CARBAMATES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-04-27 — — WO disclosed
EP-2593425-B1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE AGIOS PHARMACEUTICALS INC (US) 2018-10-17 — — EP disclosed
EP-3228325-A1 PROTEIN-POLYMER-DRUG CONJUGATES Mersana Therapeutics, Inc. (US) 2017-10-11 — — EP disclosed
EP-2717916-B1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS INC (US) 2017-03-08 — — EP disclosed
US-20160264621-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2016-09-15 — — US disclosed
US-20130184222-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2013-07-18 — — US disclosed
EP-2593425-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE Agios Pharmaceuticals, Inc. (US) 2013-05-22 — — EP disclosed
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-07-19 — — US disclosed
CN-1175043-C Sealing material composition for liquid crystal 三井化学株式会社 2004-11-10 — — CN disclosed
US-5614498-A OLIGOPEPTIDES, BRONCHDILATORS BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-03-25 — — US disclosed
US-5496928-A Endothelin antagonistic substance BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-03-05 — — US disclosed
EP-0555537-A2 Endothelin antagonistic substance BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-18 — — EP disclosed
EP-0011712-B1 PREPARATION OF BENZALDEHYDE DIALKYL ACETALS SUBSTITUTED IN THE 4-POSITION BASF Aktiengesellschaft (DE) 1983-06-15 — — EP disclosed
US-4284825-A INTERMEDIATES FOR PERFUMES, CROP PROTECTION AGENTS BASF AKTIENGESELLSCHAFT (DE) 1981-08-18 — — US disclosed
EP-0011712-A2 Preparation of benzaldehyde dialkyl acetals substituted in the 4-position BASF Aktiengesellschaft (DE) 1980-06-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same CNR1, CNR2, OPRD1 RAB9A 766/4885KMT2A 1998/4885ALDH1A1 2888/4885
US-20130184222-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A RAB9A 1278/4885KMT2A 234/4885ALDH1A1 597/4885
US-20160264621-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A RAB9A 1278/4885KMT2A 234/4885ALDH1A1 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.